

Thermo Fisher introduces new reproductive health assays to accelerate fertility research

17 July 2023 | News

Combined with the Ion Torrent Genexus Integrated Sequencer, new assays deliver valuable genomic insights in the field of aneuploidy analysis

To extend the benefits of genomic testing research for reproductive health labs, American firm Thermo Fisher Scientific has launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform *in vitro* fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.

The Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit mark the first research use reproductive health assays available on the Ion Torrent Genexus Integrated Sequencer, delivering complete workflows from sample to result for aneuploidy analysis.

Across all regions of the world, approximately 17.5% of the adult population experiences infertility. Subsequently, the use of assisted reproductive technology (ART), such as IVF procedures, is growing and has more than doubled over the past decade. PGT-A testing identifies chromosomal abnormalities in embryo samples and has become commonplace in IVF and ICSI research to advance future options for fertility care.

With the ReproSeq PGT-A Kit now available on the Genexus Integrated Sequencer, more labs will have the ability to explore comprehensive PGT-A analysis. Using the ReproSeq PGT-A Kit, researchers can study vital scientific and genetic insights that may increase the probability of success for future pregnancies and improve the health of future generations.